Go Pro
NASDAQ:SLGL

Sol-Gel Technologies Q2 2025 Earnings Report

Sol-Gel Technologies logo
$72.00 -1.00 (-1.37%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$71.90 -0.11 (-0.15%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sol-Gel Technologies EPS Results

Actual EPS
$4.17
Consensus EPS
-$0.67
Beat/Miss
Beat by +$4.84
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$17.26 million
Expected Revenue
$2.86 million
Beat/Miss
Beat by +$14.40 million
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Sol-Gel Technologies' Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules

Earnings Documents

Sol-Gel Technologies Earnings Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL) is an Israeli specialty pharmaceutical company focused on developing topical dermatological treatments. The company uses proprietary microencapsulation technology designed to improve the delivery, stability, and tolerability of active pharmaceutical ingredients applied to the skin.

Sol-Gel’s products include TWYNEO Cream, a topical combination of tretinoin and benzoyl peroxide for acne, and EPSOLAY Cream, a microencapsulated benzoyl peroxide treatment for inflammatory lesions associated with rosacea. Both products have received approval from the U.S. Food and Drug Administration and are commercialized in the United States through a licensing arrangement with Galderma.

Founded in 1997 and headquartered in Ness Ziona, Israel, Sol-Gel Technologies serves the dermatology market primarily through partnerships supporting the development and commercialization of its prescription products. The company also continues to develop additional topical treatments using its proprietary drug-delivery platform.

View Sol-Gel Technologies Profile